Stocktoria

Bausch & Lomb Corp BLCO

NYSE · stock · Ophthalmic Goods · website · IPO 2022-05-06 · LEI

Bausch & Lomb Corp financials (annual)

Revenue
$3.77B $3.77B $4.15B $4.79B $5.10B 20212022202320242025
Net income
$182.0M $6.0M -$260.0M -$317.0M -$360.0M 20212022202320242025
Free cash flow
$680.0M $170.0M -$198.0M -$59.0M -$66.0M 20212022202320242025

Bars are annual figures from 2021 to 2025; red bars are negative (a loss or cash outflow).

MetricFY2025FY2024FY2023FY2022FY2021
Revenue$5.1B$4.8B$4.1B$3.8B$3.8B
SG&A expense$2.2B$2.1B$1.7B$1.5B$1.4B
Operating income$113.0M$162.0M$130.0M$207.0M$329.0M
Income tax$35.0M$71.0M$82.0M$58.0M$125.0M
Net income-$360.0M-$317.0M-$260.0M$6.0M$182.0M
EPS (diluted)$-1.02$-0.90$-0.74$0.02$0.52
Operating cash flow$283.0M$232.0M-$17.0M$345.0M$873.0M
Free cash flow-$66.0M-$59.0M-$198.0M$170.0M$680.0M
Cash & equivalents$383.0M$305.0M$331.0M$354.0M$174.0M
Inventory$976.0M$1.0B$1.0B$628.0M$572.0M
Total assets$14.0B$13.5B$13.4B$11.1B$10.8B
Total liabilities$7.5B$6.9B$6.5B$4.0B$1.4B
Shareholders' equity$6.5B$6.5B$6.9B$7.1B$9.4B

Growth · year-over-year · Revenue CAGR 7.9%

MetricFY2025FY2024FY2023FY2022FY2021
Revenue growth+6.5%+15.6%+10.0%+0.1%
Net income growth-4433.3%-96.7%
EPS growth-3800.0%-96.2%
Free cash flow growth-216.5%-75.0%

Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.